The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Promising therapies and approaches for systemic mastocytosis
In this video, Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, briefly discusses promising therapies being investigated for systemic mastocytosis (SM), including TL-895 and elenestinib. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, Telios, a TL895 drug, it isn’t a c-KIT inhibitor directly, but it is a KIT inhibitor, looking at downstream signaling. The phase one of the trials shows promising results, we’re waiting for the phase two outcome. So improvement in patient symptoms, which is great. Harbor Elenestinib, so moving forward to another potent TKI, being used to look longitudinally at 12 months of reduction in anaphylaxis, looking at bone disease, improvement in osteoporosis, osteopenia, which is a signal that’s come up from the Pioneer trial...
So, Telios, a TL895 drug, it isn’t a c-KIT inhibitor directly, but it is a KIT inhibitor, looking at downstream signaling. The phase one of the trials shows promising results, we’re waiting for the phase two outcome. So improvement in patient symptoms, which is great. Harbor Elenestinib, so moving forward to another potent TKI, being used to look longitudinally at 12 months of reduction in anaphylaxis, looking at bone disease, improvement in osteoporosis, osteopenia, which is a signal that’s come up from the Pioneer trial. And I think moving forward for the advanced SM patients, looking at perhaps combination therapy, always looking at different ways to stop that mast cell from either degranulating, causing mediator symptoms or causing end organ damage. There’s still a long way to go, but exciting times.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
